Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up - Should You Buy?

Key Points

• Structure Therapeutics Inc. shares gapped up to $24.86 before trading on Monday, after closing at $23.58, with a last traded price of $24.23.
• Despite a recent earnings miss, multiple analysts have given the stock a consensus rating of Buy, with target prices ranging from $60 to $90.
• Hedge funds now hold 91.78% of Structure Therapeutics' shares, indicating strong institutional interest in the company.

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report) gapped up before the market opened on Monday . The stock had previously closed at $23.58, but opened at $24.86. Structure Therapeutics shares last traded at $24.23, with a volume of 252,437 shares traded.

Analyst Upgrades and Downgrades

GPCR has been the topic of a number of research reports. Lifesci Capital upgraded shares of Structure Therapeutics to a "strong-buy" rating in a report on Monday, September 8th. HC Wainwright dropped their target price on shares of Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. Guggenheim dropped their target price on shares of Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $65.00 target price on shares of Structure Therapeutics in a report on Monday, June 23rd. Finally, JMP Securities dropped their target price on shares of Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating on the stock in a report on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company. Based on data from MarketBeat.com, Structure Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $68.67.

Structure Therapeutics Stock Down 1.4%

The stock has a market capitalization of $1.39 billion, a PE ratio of -23.37 and a beta of -1.89. The stock's 50-day moving average is $19.31 and its 200 day moving average is $20.65.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.08). As a group, equities research analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current year.

Institutional Trading of Structure Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. acquired a new stake in Structure Therapeutics in the fourth quarter valued at approximately $34,000. State of Wyoming acquired a new stake in Structure Therapeutics in the second quarter valued at approximately $28,000. Assetmark Inc. lifted its stake in shares of Structure Therapeutics by 39.9% in the second quarter. Assetmark Inc. now owns 2,877 shares of the company's stock worth $60,000 after buying an additional 820 shares during the last quarter. National Bank of Canada FI lifted its stake in shares of Structure Therapeutics by 1,448.2% in the first quarter. National Bank of Canada FI now owns 2,957 shares of the company's stock worth $51,000 after buying an additional 2,766 shares during the last quarter. Finally, ANTIPODES PARTNERS Ltd lifted its stake in shares of Structure Therapeutics by 310.7% in the first quarter. ANTIPODES PARTNERS Ltd now owns 4,247 shares of the company's stock worth $74,000 after buying an additional 3,213 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.